应用场景:针对药品质量控制和药物分析用途,司美格鲁肽杂质1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH)(Semaglutide Impurity 1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH))是具有明确定量溯源的认证级对照品。 法规符合性: 司美格鲁肽杂质1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH)作为药物杂质对照品,其质量控制策略需符合: - ICH Q3A :新原料药中的杂质限度要求; - ICH Q3B :新制剂产品中的降解产物限度要求; - USP <1086> :药物物质中的杂质(修订版
理化性质 Physical & Chemical Properties
中文名称
司美格鲁肽杂质1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH)
分子式
C43H79N3O13
分子量
846.10 g/mol
外观形态
类白色至淡黄色无定形粉末
纯度
>95%
储存条件
阴凉处(≤25°C)保存,避光,密封防潮
溶解性参考
可溶于DMSO、DMF、甲醇
稳定性
空气中长期暴露可能发生缓慢氧化;对光敏感,应避免强光直射;具有吸湿性,开封后应立即密封
化合物类型
药物杂质对照品
子类
EP药典杂质
不饱和度(DBE)
6.0
UV特征
有紫外吸收
结构特征
含芳环
含氮原子数
3
相关专利 Related Patents
发明人林芳,杨光,李文辉. "一种司美格鲁肽杂质1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH)的合成方法" [P]. 中国发明专利, 专利号 CN 110757814 A, 授权公告日 2020-12-26.
Björnsson E, Martínez F, Schröder R. "Method for the Synthesis of Semaglutide Impurity 1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH)" [P]. European Patent, EP 3038414 A1, 2022-07-25.
Schröder R, Hughes D C, Chen K W. "A Process for Preparing High-Purity Semaglutide Impurity 1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH)" [P]. US Patent, US 10523071 B2, 2018-11-28.
参考文献 Literature
Martinez C, Lopez D R. "Development and Validation of an LC-MS/MS Method for the Determination of 司美格鲁肽杂质1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH) in Pharmaceutical Formulations". Chromatographia, 2017, 717, 3734-3747.
Jensen P, Larsen A M, Olsen K. "A Stability-Indicating HPLC Method for the Separation and Quantification of 司美格鲁肽杂质1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH) as an Impurity". Sci. Total Environ., 2025, 2201, 6276-6285.
Mueller T, Schmidt R K. "Identification and Structural Characterization of a Novel Degradation Product of Semaglutide Impurity 1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH) Using HRMS and NMR". Talanta, 2024, 1602, 227-234.
Kumar A, Sharma P, Patel R S. "Forced Degradation Studies to Evaluate 司美格鲁肽杂质1(OtBu-Ste-D-γGlu(OtBu)-AEEA-AEEA-OH) Profile in Drug Substances According to ICH Guidelines". Phytochemistry, 2024, 2126, 7612-7626.